MGRX (STOCKS)
Mangoceuticals, Inc. Common Stock
$0.409400
+0.069400 (+20.41%)
Prev close: $0.340000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jacob D. Cohen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $6.87M
- Employees
- 3
- P/E (TTM)
- -0.14
- P/B (TTM)
- 0.36
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.69 | $0.00 | +0.0000 | +0.00% |
Financial Statements
| Revenues | $456.02K |
| Benefits Costs and Expenses | $21.10M |
| Cost Of Revenue | $54.42K |
| Costs And Expenses | $21.10M |
| Gross Profit | $250.39K |
| Nonoperating Income/Loss | -$2.61M |
| Operating Expenses | $18.28M |
| Operating Income/Loss | -$18.03M |
| Income/Loss From Continuing Operations After Tax | -$20.64M |
| Income/Loss From Continuing Operations Before Tax | -$20.64M |
| Net Income/Loss | -$20.64M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$461.00 |
| Net Income/Loss Attributable To Parent | -$20.64M |
| Net Income/Loss Available To Common Stockholders, Basic | -$21.82M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $1.18M |
| Preferred Stock Dividends And Other Adjustments | $1.18M |
| Basic Earnings Per Share | -$2.17 |
| Diluted Earnings Per Share | -$2.17 |
| Basic Average Shares | 10,071,609 |
| Diluted Average Shares | 10,071,609 |
| Assets | $16.09M |
| Current Assets | $1.55M |
| Noncurrent Assets | $14.54M |
| Fixed Assets | $1.79K |
| Intangible Assets | $14.23M |
| Other Non-current Assets | $307.86K |
| Liabilities | $890.57K |
| Current Liabilities | $890.57K |
| Noncurrent Liabilities | $0.00 |
| Equity | $15.20M |
| Equity Attributable To Noncontrolling Interest | -$1.54K |
| Equity Attributable To Parent | $15.20M |
| Liabilities And Equity | $16.09M |
| Net Cash Flow From Operating Activities | -$5.85M |
| Net Cash Flow From Operating Activities, Continuing | -$5.85M |
| Net Cash Flow From Investing Activities | -$1.42M |
| Net Cash Flow From Investing Activities, Continuing | -$1.42M |
| Net Cash Flow From Financing Activities | $7.27M |
| Net Cash Flow From Financing Activities, Continuing | $7.27M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$20.65M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$1.54K |
| Comprehensive Income/Loss Attributable To Parent | -$20.64M |
| Other Comprehensive Income/Loss | -$2.76K |